GSK Smoking Cessation Business Returns To Positive Growth In Q3
This article was originally published in The Tan Sheet
Executive Summary
Sales gains in GlaxoSmithKline's smoking cessation franchise - the first in over a year - helped the firm's OTC drug segment and overall consumer business to a single-digit sales increase in the third quarter.
You may also be interested in...
Generic Nicotine Replacement Products Start To Smoke In 2000
Private label OTC smoking cessation products thrived in 2000, their first full year on the food, drug and mass market, recording sales well over $100 mil. and capturing nearly a 20% dollar share, according to data from Information Resources, Inc. (Chicago).
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands